1. Indirect induction of regulatory T cells accompanies immune responses during peptide vaccination of chronic lymphocytic leukaemia patients.

    British Journal of Haematology 174(1):155 (2016) PMID 26304747

  2. Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantation.

    International Journal of Cancer 138(7):1792 (2016) PMID 26519872

    Wilms' tumor gene 1 (WT1) is overexpressed in leukemia and WT1-derived CD8(+) T-cell epitopes for immunotherapies targeting WT1 have been defined. Here, we analyzed expression of WT1 in 226 peripheral blood and bone marrow samples from patients with acute myeloid leukemia or myelodysplastic synd...
  3. Positron annihilation signatures associated with the outburst of the microquasar V404 Cygni.

    Nature 531(7594):341 (2016) PMID 26934231

    Microquasars are stellar-mass black holes accreting matter from a companion star and ejecting plasma jets at almost the speed of light. They are analogues of quasars that contain supermassive black holes of 10(6) to 10(10) solar masses. Accretion in microquasars varies on much shorter timescales...
  4. Leukemic progenitor cells are susceptible to targeting by stimulated cytotoxic T cells against immunogenic leukemia-associated antigens.

    International Journal of Cancer 137(9):2083 (2015) PMID 25912930

    Leukemic stem cells (LSC) might be the source for leukemic disease self-renewal and account for disease relapse after treatment, which makes them a critical target for further therapeutic options. We investigated the role of cytotoxic T-lymphocytes (CTL) counteracting and recognizing LSC. Leukem...
  5. A very luminous magnetar-powered supernova associated with an ultra-long γ-ray burst.

    Nature 523(7559):189 (2015) PMID 26156372

    A new class of ultra-long-duration (more than 10,000 seconds) γ-ray bursts has recently been suggested. They may originate in the explosion of stars with much larger radii than those producing normal long-duration γ-ray bursts or in the tidal disruption of a star. No clear supernova has yet been...
  6. T cell-based targeted immunotherapies for patients with multiple myeloma.

    International Journal of Cancer 136(8):1751 (2015) PMID 25195787

    Despite high-dose chemotherapy followed by autologs stem-cell transplantation as well as novel therapeutic agents, multiple myeloma (MM) remains incurable. Following the general trend towards personalized therapy, targeted immunotherapy as a new approach in the therapy of MM has emerged. Better ...
  7. Early ⁵⁶Ni decay gamma rays from SN2014J suggest an unusual explosion.

    Science 345(6201):1162 (2014) PMID 25081484

    Type Ia supernovae result from binary systems that include a carbon-oxygen white dwarf, and these thermonuclear explosions typically produce 0.5 solar mass of radioactive (56)Ni. The (56)Ni is commonly believed to be buried deeply in the expanding supernova cloud. In SN2014J, we detected the lin...
  8. Frequent T cell responses against immunogenic targets in lung cancer patients for targeted immunotherapy.

    Oncology Reports 31(1):384 (2014) PMID 24154794

    To date, lung cancer is one of the leading causes of cancer mortality with short overall survival despite adequate therapy. New immunotherapeutic strategies using peptides derived from tumor-associated antigens (TAAs) can induce a specific cytotoxic T cell (CTL) response leading to a targeted tu...
  9. A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies.

    Leukemia Research 37(9):1100 (2013) PMID 23746966

    A phase I dose-escalation study of MSC1992371A, an oral aurora kinase inhibitor, was carried out in patients with hematologic malignancies. Patients received escalating doses either on days 1-3 and 8-10 (n=36) or on days 1-6 (n=39) of a 21-day cycle. The maximum tolerated doses were 37 and 28 mg...
  10. Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut).

    Blood 122(6):1087 (2013) PMID 23929838

  11. Specific immune responses against epitopes derived from Aurora kinase A and B in acute myeloid leukemia.

    Leukemia & Lymphoma 54(7):1500 (2013) PMID 23101751

    Aurora kinases are serine/threonine kinases which play an important role in the process of mitosis and cell cycle regulation. Aurora kinase inhibitors are described to sensitize malignant cells to cytosine arabinoside and specific antibodies by mediating apoptosis. Aurora kinases are overexpress...
  12. PRAME-induced inhibition of retinoic acid receptor signaling-mediated differentiation--a possible target for ATRA response in AML without t(15;17).

    Clinical Cancer Research 19(9):2562 (2013) PMID 23444226

    In acute myeloid leukemia (AML) without retinoic acid receptor (RAR) rearrangement, the effect of all-trans-retinoic acid (ATRA) is still poorly understood despite an association of NPM1 mutation and ATRA response. Recently, preferentially expressed antigen in melanoma (PRAME) has been shown to ...
  13. Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis.

    Mycoses 56(3):304 (2013) PMID 23170837

    Invasive aspergillosis is an important cause of morbidity and mortality in haematological patients. Current guidelines recommend voriconazole as first-line therapy. A change in class of antifungal agent is generally recommended for salvage therapy. The focus of this analysis was to assess if pos...
  14. Donor lymphocyte infusion induces polyspecific CD8(+) T-cell responses with concurrent molecular remission in acute myeloid leukemia with NPM1 mutation.

    Journal of Clinical Oncology 31(3):e44 (2013) PMID 23248243

  15. Bright radio emission from an ultraluminous stellar-mass microquasar in M 31.

    Nature 493(7431):187 (2013) PMID 23235823

    A subset of ultraluminous X-ray sources (those with luminosities of less than 10(40) erg s(-1); ref. 1) are thought to be powered by the accretion of gas onto black holes with masses of ∼5-20M cicled dot, probably by means of an accretion disk. The X-ray and radio emission are coupled in such Ga...
  16. Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial.

    Haematologica 97(9):e34 (2012) PMID 22952334 PMCID PMC3436225

  17. Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia.

    Blood 120(6):1282 (2012) PMID 22592607

    Mutations in the nucleophosmin gene (NPM1(mut)) are one of the most frequent molecular alterations in acute myeloid leukemia (AML), and immune responses may contribute to the favorable prognosis of AML patients with NPM1(mut). In the present study, we were able to demonstrate both CD4(+) and CD8...
  18. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial.

    Journal of Clinical Oncology 30(20):2492 (2012) PMID 22585697 PMCID PMC4874149

    To compare the receipt of clofarabine plus cytarabine (Clo+Ara-C arm) with cytarabine (Ara-C arm) in patients ≥ 55 years old with refractory or relapsed acute myelogenous leukemia (AML). Patients were randomly assigned to receive either clofarabine (Clo) 40 mg/m(2) or a placebo followed by Ara-C...
  19. Immunogenic targets for specific immunotherapy in multiple myeloma.

    Clinical and Developmental Immunology 2012:820394 (2012) PMID 22611422 PMCID PMC3352660

    Multiple myeloma remains an incurable disease although the prognosis has been improved by novel therapeutics and agents recently. Relapse occurs in the majority of patients and becomes fatal finally. Immunotherapy might be a powerful intervention to maintain a long-lasting control of minimal res...
  20. The immunodominant CD8 T cell response to the human cytomegalovirus tegument phosphoprotein pp65(495-503) epitope critically depends on CD4 T cell help in vaccinated HLA-A*0201 transgenic mice.

    Journal of Immunology 187(5):2172 (2011) PMID 21810614

    Immunodominance hierarchies operating in immune responses to viral Ags limit the diversity of the elicited CD8 T cell responses. We evaluated in I-A(b+)/A2-HHD-II and HLA-DR1(+)/A2-DR1 mice the HLA-A*0201-restricted, multispecific CD8 T cell responses to the human CMV tegument phosphoprotein pp6...